BXRX Baudax Bio Inc - Ordinary Shares

6.67
+0.34  (+5%)
Previous Close 6.33
Open 6.41
Price To Book -1.71
Market Cap 60,554,929
Shares 9,078,700
Volume 262,754
Short Ratio
Av. Daily Volume 0
Stock charts supplied by TradingView

NewsSee all news

  1. Baudax Bio to Present at the Piper Jaffray 31st Annual Healthcare Conference

    MALVERN, Pa., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Baudax Bio, Inc., (NASDAQ:BXRX) a pharmaceutical company focused on advancing non-opioid analgesics and other products for the hospital and other acute care settings,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

First CRL announced May 24, 2018. Second CRL issued March 22, 2019. Intends to appeal decision.
Intravenous (IV) meloxicam
Acute pain following bunionectomy surgery
Phase 1 trial to be initiated 1H 2020.
RP-1000

Latest News

  1. Baudax Bio to Present at the Piper Jaffray 31st Annual Healthcare Conference

    MALVERN, Pa., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Baudax Bio, Inc., (NASDAQ:BXRX) a pharmaceutical company focused on advancing non-opioid analgesics and other products for the hospital and other acute care settings,